In this study, we used three pluripotent hESC lines, Regea08/017, Regea08/023, and Regea11/013, that have been derived and characterized in our laboratory
38 and cultured and differentiated as previously described.
39,40 Briefly, the hESC lines were cultured on top of mitomycin (10 μg/mL; Sigma-Aldrich Corp., St. Louis, MO, USA) treated human foreskin fibroblast feeder cells (CRL-2429TM; ATCC, Manassas, VA, USA). The hESCs were cultured at 37°C and 5% CO
2 with hESC culture medium consisting of knockout Dulbecco's modified Eagle's medium supplemented with 20% Knock-Out Serum Replacement (KO-SR), 2 mM Glutamax-I, 0.1 mM 2-mercaptoethanol (all from Life Technologies, Carlsbad, CA, USA), 1% nonessential amino acids, 50 U/m penicillin/streptomycin (both from Lonza Group Ltd., Basel, Switzerland), and 8 ng/mL human BFGF (Peprotech, London, UK). The culture medium was changed five times a week, and undifferentiated colonies were enzymatically selected onto new feeder cells every 10 days. The undifferentiated hESCs were manually selected and induced to differentiate into RPE cells in floating cell aggregates by reducing the KO-SR concentration to 15% and removing the BFGF, as previously described in Reference 40. Thereafter, floating aggregates were cultured for 70 to 155 days (
Table 1). The culture medium (RPEbasic
40) was replenished three times per week. Thereafter, pigmented areas of floating aggregates were dissected, dissociated with 1× Trypsin-EDTA, and replated on human placental collagen IV (5 μg/cm
2; Sigma-Aldrich Corp.) for enrichment of cell number as described in Reference 39.